Cargando…

Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis

Glucocorticoids are commonly prescribed medications to treat multiple diseases across many medical specialties. One of the most common yet largely unappreciated side effect of glucocorticoid use is increased risk of fracture. Many different therapies are indicated to prevent and treat this condition...

Descripción completa

Detalles Bibliográficos
Autor principal:	Dore, Robin K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3663438/ https://www.ncbi.nlm.nih.gov/pubmed/23717037 http://dx.doi.org/10.2147/PPA.S31067

Ejemplares similares

Management of glucocorticoids-induced osteoporosis: role of teriparatide
por: Migliaccio, Silvia, et al.
Publicado: (2009)

Role of teriparatide in treatment of glucocorticoid-induced osteoporosis
por: Lau, Arthur N, et al.
Publicado: (2010)

Update on the safety and efficacy of teriparatide in the treatment of osteoporosis
por: Minisola, Salvatore, et al.
Publicado: (2019)

Teriparatide in the management of osteoporosis
por: Bodenner, Donald, et al.
Publicado: (2007)

Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy
por: Taylor, Adam D, et al.
Publicado: (2019)

Profile of teriparatide in the management of postmenopausal osteoporosis
por: Sikon, Andrea, et al.
Publicado: (2010)

Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis
por: Inderjeeth, Charles A, et al.
Publicado: (2014)

Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
por: Seno, Takahiro, et al.
Publicado: (2016)

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020)

Efficacy and safety of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis
por: Serefoglu, Ege Can, et al.
Publicado: (2010)

Teriparatide – Indications beyond osteoporosis
por: Cheng, Marilyn Lee, et al.
Publicado: (2012)

Therapy of Osteoporosis in Men with Teriparatide
por: Cusano, Natalie E., et al.
Publicado: (2011)

Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
por: Yuan, Chuanjian, et al.
Publicado: (2023)

Teriparatide for osteoporosis: importance of the full course
por: Lindsay, R., et al.
Publicado: (2016)

The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden
por: Murphy, Daniel R, et al.
Publicado: (2012)

The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta-analysis and systematic review of randomized controlled trials
por: Liu, Zhi-Ming, et al.
Publicado: (2022)

Comparative Effects of Teriparatide and Risedronate in Glucocorticoid-Induced Osteoporosis in Men: 18-Month Results of the EuroGIOPs Trial
por: Glüer, Claus-C, et al.
Publicado: (2013)

A Case of Teriparatide on Pregnancy-Induced Osteoporosis
por: Lee, Seok Hong, et al.
Publicado: (2013)

An effect comparison of alendronate and teriparatide in patients with glucocorticoid-induced osteoporosis: A protocol for systematic review and meta-analysis
por: Liang, Na, et al.
Publicado: (2022)

Efficacy and Safety of Teriparatide in Beta-Thalassemia Major Associated Osteoporosis: A Real-Life Experience
por: Gagliardi, Irene, et al.
Publicado: (2022)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Improvement in Glucocorticoid-Induced Osteoporosis on Switching from Bisphosphonates to Once-Weekly Teriparatide: A Randomized Open-Label Trial
por: Nanki, Toshihiro, et al.
Publicado: (2022)

Treatment of osteoporosis with teriparatide: The Slovenian experience
por: Kocjan, Tomaz, et al.
Publicado: (2021)

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab
por: Anastasilakis, Athanasios D, et al.
Publicado: (2012)

Effects of teriparatide in Chinese and Caucasian women with osteoporosis: bridging study on efficacy
por: Xie, Zhongjian, et al.
Publicado: (2019)

Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment
por: Gagnon, Claudia, et al.
Publicado: (2008)

Glucocorticoid-induced osteoporosis: an update
por: Compston, Juliet
Publicado: (2018)

Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis
por: Farahmand, P., et al.
Publicado: (2013)

Update on Glucocorticoid Induced Osteoporosis
por: Cho, Soo-Kyung, et al.
Publicado: (2021)

The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis
por: Hasegawa, Eriko, et al.
Publicado: (2018)

PINP as a biological response marker during teriparatide treatment for osteoporosis
por: Krege, J. H., et al.
Publicado: (2014)

Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options
por: Payer, Juraj, et al.
Publicado: (2010)

Dilemmas in the diagnosis and management of osteoporosis in a patient with alkaptonuria: Successful treatment with teriparatide
por: Ebrahim, Ismail C., et al.
Publicado: (2022)

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis
por: Sun, Yang, et al.
Publicado: (2022)

Glucocorticoid‐induced osteoporosis in rheumatic diseases
por: Pereira, Rosa Maria Rodrigues, et al.
Publicado: (2010)

Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update
por: Messalli, Enrico M, et al.
Publicado: (2010)

Safety and efficacy in actual clinical practice of once-weekly subcutaneous teriparatide for osteoporosis patients with a high fracture risk
por: Ifuku, Emiko, et al.
Publicado: (2019)

Treatment responses with once-weekly teriparatide therapy for osteoporosis
por: Shiraki, M., et al.
Publicado: (2016)

Short-Term Treatment With Teriparatide Restores Independent Ambulation in a Patient With Glucocorticoid-Induced Osteonecrosis of the Knees and Ankles
por: Chen, Xin, et al.
Publicado: (2021)

Glucocorticoid-induced osteoporosis
por: Briot, Karine, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6v4vr5ndbgv5rtpju32l7t17cg